Innovent Biologics (HK:1801) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Innovent Biologics has received approval from China’s National Medical Products Administration for its drug Dovbleron, a next-generation treatment for ROS1-positive non-small cell lung cancer. This marks the 13th addition to Innovent’s portfolio, highlighting the company’s commitment to innovative cancer therapies. The approval follows positive results from a pivotal Phase 2 trial, showcasing significant efficacy in patients.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue